Navigation Links
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Date:3/10/2009

CAMBRIDGE, Mass., March 10 /PRNewswire/ -- Tolerx, Inc., today announced that DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes patients in Europe. In DEFEND, preserving beta cell function subsequent to the administration of otelixizumab is the primary outcome that is being evaluated. This outcome will be assessed by measuring C-peptide levels (a surrogate of endogenous insulin secretion) and by measuring reductions in the amount of injected insulin used to maintain excellent glycemic control.

DEFEND continues to actively recruit subjects in the United States, Canada, Sweden, Finland, Germany, Italy, and the UK. Tolerx anticipates that enrollment will soon commence at clinical sites in Spain and Denmark.

"Our participation in DEFEND reflects our research priorities to support the development of innovative immune intervention for type 1 diabetes patients. We have begun dosing otelixizumab in DEFEND and are excited about its potential to be an effective treatment option for type 1 diabetics," stated Dr. Paolo Pozzilli, Professor University Campus Bio-Medico, Rome Italy.

"We are pleased that an increasing number of excellent clinical researchers in Europe and North America have started DEFEND at their sites and look forward to their continued participation in this important effort. We believe that a single short course of otelixizumab may have the potential to preserve residual beta cell function and offer people with autoimmune type 1 diabetes improved disease control" said Dr. Louis Vaickus, Chief Medical Officer of Tolerx. He continued "We are seeking in DEFEND to conclusively demonstrate this understanding."

About the DEFEND Study

DEFEND is a
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
2. Laureate Announces Manufacturing Agreement with Tolerx
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
5. BioLife Solutions Expands Scientific Advisory Board
6. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Pharsight Expands Strategic Consulting Services Team
9. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
10. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
11. AQUISS Expands Into Significant New Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... is in the middle of two transitions; one in ... will play a critical role in both. Wittwer, who officially ... the remainder of the company's transformation from a phone company ... WTN Media interviewed Wittwer about the leadership transition. In ...
... on intellectual property law. In Part II, attorney ... of trademarks and patents. , , In ... directors liable for their corporation's infringing acts. It is ... a personal liability so that corporate officers and directors ...
... was introduced a month ago, and already Microsoft's Windows Vista ... has been bruised by critical media reports about security flaws and ... have tested the beta version. We posed several questions to Justin ... director of information technologies for Veridian Homes , to get ...
Cached Biology Technology:New CEO at TDS on tech innovation and leadership (Part 1) 2New CEO at TDS on tech innovation and leadership (Part 1) 3New CEO at TDS on tech innovation and leadership (Part 1) 4IP infringement - avoiding liability for officers & directors 2IP infringement - avoiding liability for officers & directors 3IP infringement - avoiding liability for officers & directors 4Wisconsin firms won't rush to adopt Microsoft Vista 2Wisconsin firms won't rush to adopt Microsoft Vista 3Wisconsin firms won't rush to adopt Microsoft Vista 4
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... Although scientists have known for centuries that many bacteria ... a toxic by-product of cellular activity. Now, researchers at ... a major role in protecting bacteria from the effects of ... Evgeny Nudler, PhD, the Julie Wilson Anderson Professor of Biochemistry ...
... trees, as in other plants, the energy used to ... solar radiation through the process of photosynthesis. Peach tree ... and effectiveness in distributing and using carbohydrates. A basic ... whole-tree level can aid growers in understanding how peach ...
... were on the brink of extinction until Lindsay Oaks and ... observational and forensic studies to find out why the number ... were being poisoned by residues of an anti-inflammatory drug (diclofenac) ... on. The work is presented in a chapter of the ...
Cached Biology News:Targeting bacterial gas defenses allow for increased efficacy of numerous antibiotics 2Introducing L-PEACH: Tool for understanding peach tree development 2Vultures dying at alarming rate 2
Functionally tested for consistent G-banding of chromosomes....
... BacVector Insect Cell Medium is optimized for ... Insect Cells. In this protein-free medium, Sf9 ... * 107 cells/ml with viabilities above 95%. ... assays, where color from X-gluc staining of ...
... Grace's Insect Medium is formuatled for ... including Sf9 and Sf21 cells. Grace's ... transfectioin because it does not contain ... interfere with transfection. Grace's Insect Medium, ...
TNM-FH Insect Medium 1 liter...
Biology Products: